Skip to main content

International Stem Cell Corporation

ApplicationSan Diego, CA, USAFounded 2001· One of 381 Application companies tracked by AMPulse

Develops parthenogenetic stem cell (hpSC) technology for regenerative medicine, enabling immune-matched cell therapies and research products, with applications in bioprinting and tissue engineering.

CEO / Founder
Andrey Semechkin, PhD
Team Size
11-50
Stage
Active
Total Funding
$8.8M
Latest Round
Strategic Investment
Key Investors
Andrey Semechkin

Technology & Products

Key Products

Develops human parthenogenetic stem cell (hpSC) technology for regenerative medicine, targeting central nervous system, joint, and liver diseases. Also offers specialized cells and growth media for research and stem cell-based anti-aging products through its Lifeline Skin Care unit.

Technological Advantage

Patented parthenogenetic process allows creation of stem cell lines that match millions of individuals, reducing immune rejection in therapies; technology is defensible via patents and trade secrets.

Differentiation

Value Proposition

Provides immune-matched stem cells via parthenogenesis, reducing rejection risks in therapies and offering scalable cell lines for research and cosmetic applications, potentially lowering development costs and time-to-market.

How They Differentiate

Focus on parthenogenetic stem cells for immune-matching vs. competitors using traditional embryonic or adult stem cells; offers scalable cell banking and research products through subsidiaries.

Market & Competition

Target Customers

Biotechnology researchers, pharmaceutical companies, cosmetic industry, regenerative medicine clinics

Industry Verticals

Biotechnology; Pharmaceuticals; Cosmetics; Regenerative Medicine

Competitors

Thermo Fisher Scientific, STEMCELL Technologies, Merck KGaA

Growth & Milestones

Growth Metrics

Revenue increased to $9.09 million in 2024, a 17% increase compared to $7.79 million in 2023, with combined operating income from subsidiaries reaching $2.39 million in 2024, a 29% increase from $1.85 million in 2023.

Major Milestones

Development of first parthenogenetic homozygous stem cell line; Launch of UniStemCell™ bank initiative; Establishment of Lifeline Cell Technology and Lifeline Skin Care subsidiaries

https://www.intlstemcell.com

Why this company matters

International Stemcell occupies a niche in regenerative medicine by using parthenogenesis to create homozygous stem cell lines from unfertilized human eggs. This approach aims to address immune rejection, a persistent challenge in cell therapy, by producing cells that can match millions of individuals without the ethical and technical complexities of embryonic or adult stem cell methods.

The core technology, human parthenogenetic stem cells (hpSC), is protected by patents in the EU, US, Australia, and Japan. The company has developed the UniStemCell bank to scale immune-matched lines for global populations. Through subsidiaries Lifeline Cell Technology and Lifeline Skin Care, it also supplies specialized cells, growth media, and anti-aging products for research and cosmetic markets.

Target customers include biotechnology researchers, pharmaceutical companies, and regenerative medicine clinics. Applications span central nervous system, joint, and liver diseases, as well as bioprinting and tissue engineering. Revenue reached $9.09 million in 2024, up 17% year-over-year, with combined operating income from subsidiaries growing 29% to $2.39 million.

International Stemcell competes with larger players like Thermo Fisher Scientific and STEMCELL Technologies but differentiates through its parthenogenetic platform and immune-matching capability. The company's narrow focus on hpSC and reliance on a single key investor represent both its strategic moat and a concentration risk.